Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3
作者：
Schmidt, Andrew [1 ]
Azad, Arun [2 ]
Goh, Jeffrey [3 ,4 ]
Harris, Carole [5 ,6 ]
Joshua, Anthony M. [7 ]
Weickhardt, Andrew [8 ]
Krieger, Laurence [9 ]
机构：
[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia
[4] Univ Queensland, St Lucia, Qld, Australia
[5] St George Hosp, Kogarah, NSW, Australia
[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia
[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;
D O I：
10.1111/ajco.13289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
引用
收藏
页码：3 / 10
页数：8
相关论文
共 50 条
[41]   Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain [J].
Villa, Guillermo ;
Hernandez-Pastor, Luis-Javier .
BMC CANCER, 2013, 13
[42]   Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy [J].
Kawano, Yoshiaki ;
Takahashi, Wataru ;
Eto, Masatoshi ;
Kamba, Tomomi ;
Miyake, Hideaki ;
Fujisawa, Masato ;
Kamai, Takao ;
Uemura, Hirotsugu ;
Tsukamoto, Taiji ;
Azuma, Haruhito ;
Matsubara, Akio ;
Nishimura, Kazuo ;
Nakamura, Tsuyoshi ;
Ogawa, Osamu ;
Naito, Seiji .
CANCER SCIENCE, 2016, 107 (07) :1013-1017
[43]   Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma [J].
Chen, Chi-Chang ;
Hess, Gregory P. ;
Liu, Zhimei ;
Gesme, Dean H. ;
Agarwala, Sanjiv S. ;
Garay, Carlos C. ;
Hill, Jerrold W. ;
Guo, Amy .
CLINICAL GENITOURINARY CANCER, 2012, 10 (04) :256-261
[44]   Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience [J].
Abd Ghafar, Nahjatul Kursyiah ;
Alip, Adlinda ;
Ong, Teng Aik ;
Yap, Ning Yi ;
Saad, Marniza .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) :1303-1311
[45]   Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma [J].
Bianconi, Maristella ;
Faloppi, Luca ;
Loretelli, Cristian ;
Zizzi, Antonio ;
Giampieri, Riccardo ;
Bittoni, Alessandro ;
Andrikou, Kalliopi ;
Del Prete, Michela ;
Burattini, Luciano ;
Montironi, Rodolfo ;
Scartozzi, Mario ;
Cascinu, Stefano .
ONCOTARGET, 2016, 7 (25) :37599-37607
[46]   Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma [J].
Ikeda, Takashi ;
Ishihara, Hiroki ;
Takagi, Toshio ;
Kondo, Tsunenori ;
Yoshida, Kazuhiko ;
Iizuka, Junpei ;
Tanabe, Kazunari .
TARGETED ONCOLOGY, 2018, 13 (03) :379-387
[47]   Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab [J].
Singh, Abhay ;
Singh, Inderpreet ;
Singh, Namrata ;
Puzanov, Igor .
ONCOTARGETS AND THERAPY, 2020, 13 :4021-4034
[48]   First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis [J].
Wallis, Christopher J. D. ;
Klaassen, Zachary ;
Bhindi, Bimal ;
Ye, Xiang Y. ;
Chandrasekar, Thenappan ;
Farrell, Ann M. ;
Goldberg, Hanan ;
Boorjian, Stephen A. ;
Leibovich, Bradley ;
Kulkarni, Girish S. ;
Shah, Prakesh S. ;
Bjarnason, Georg A. ;
Heng, Daniel Y. C. ;
Satkunasivam, Raj ;
Finelli, Antonio .
EUROPEAN UROLOGY, 2018, 74 (03) :309-321
[49]   First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology [J].
Numakura, Kazuyuki ;
Kobayashi, Mizuki ;
Muto, Yumina ;
Sekine, Yuya ;
Takahashi, Makoto ;
Kashima, Soki ;
Yamamoto, Ryohei ;
Koizumi, Atsushi ;
Nara, Taketoshi ;
Saito, Mitsuru ;
Narita, Shintaro ;
Nanjyo, Hiroshi ;
Habuchi, Tomonori .
SCIENTIFIC REPORTS, 2020, 10 (01)
[50]   Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma [J].
Mitsogiannis, Iraklis C. ;
Mitsogianni, Maria ;
Papathanassiou, Maria ;
Anagnostou, Maria ;
Tamposis, Ioannis ;
Mitrakas, Lampros ;
Samara, Maria ;
Tzortzis, Vassilios ;
Vlachostergios, Panagiotis J. .
JOURNAL OF KIDNEY CANCER AND VHL, 2022, 9 (03) :29-40
12345